Pfizer plans to proceed with a daily oral weight loss drug called danuglipron, which is in the same category as Ozempic and Zepbound. The pharmaceutical company believes the once-daily formulation could offer a competitive profile in the oral GLP-1 space, following encouraging initial data. Danuglipron works by boosting insulin secretion and maintaining healthy blood sugar levels.
A popular fake Telegram Premium site has been flooding the web with malware – here's how to stay safe – TechRadar
A popular fake Telegram Premium site has been flooding the web with malware – here’s how to stay safe TechRadar
